Last10K.com

Galectin Therapeutics Inc (GALT) SEC Filing 8-K Material Event for the period ending Wednesday, March 6, 2019

Galectin Therapeutics Inc

HISTORY TOOLS
CIK: 1133416 Ticker: GALT

View differences made from one to another to evaluate Galectin Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Galectin Therapeutics Inc.

Continue

Assess how Galectin Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Galectin Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Galectin Therapeutics Inc provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: GALT
CIK: 1133416
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-064717
Submitted to the SEC: Wed Mar 06 2019 7:58:02 AM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Wednesday, March 6, 2019
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/galt/0001193125-19-064717.htm